RCC2

Protein RCC2 · Q9P258 · RCC2 on Sugi Atlas →

0 patent compounds predicted against RCC2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to RCC2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC) PHASE3COMPLETED
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer PHASE1/PHASE2COMPLETED
CD70-targeted immunoPET Imaging of Kidney Cancer PHASE2RECRUITING
Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma PHASE2COMPLETED
A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma PHASE2COMPLETED
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases PHASE2UNKNOWN
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer PHASE2COMPLETED
The High-Dose Aldesleukin (IL-2) Select Trial for Patients With Metastatic Renal Cell Carcinoma PHASE2COMPLETED
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer PHASE2UNKNOWN
A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours PHASE1/PHASE2COMPLETED
Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma PHASE2UNKNOWN
Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC PHASE2UNKNOWN
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma PHASE2ACTIVE_NOT_RECRUITING
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma PHASE1ACTIVE_NOT_RECRUITING
Active Immunotherapy Of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA PHASE1UNKNOWN
A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma EARLY_PHASE1COMPLETED
TRACERx Renal CAPTURE Sub-study nanUNKNOWN
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders nanRECRUITING
microRNA Expression in Renal Cell Carcinoma nanCOMPLETED
Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes nanUNKNOWN
Role of Geminin and Mcm-2 in Prognosis of Renal Cell Carcinoma nanUNKNOWN
Study of the Prognostic Impact of CD44 on Renal Cell Carcinoma nanNOT_YET_RECRUITING
Biomarkers of Renal Cancer nanRECRUITING
Renal Mass Registry nanCOMPLETED
Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma nanCOMPLETED
Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma nanUNKNOWN
The Natural History of Small Renal Masses nanCOMPLETED
Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma nanCOMPLETED
Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma nanCOMPLETED
Preventive Effects of Aspirin as Adjuvant Therapy in Patients With Locally Advanced Renal Cell Carcinoma nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a RCC2 binder may also engage these)

ProteinNameSimilarity
Q8BK67 0.999 Q8BK67 →
Q6NYE2 0.990 Q6NYE2 →
Q52KW8 0.987 Q52KW8 →
Q96I51 0.959 Q96I51 →
Q9CYF5 0.953 Q9CYF5 →
O88506 0.949 O88506 →
Q6P9R2 0.945 Q6P9R2 →
Q9Z1W9 0.945 Q9Z1W9 →
A4IIX9 0.944 A4IIX9 →
Q6DDF0 0.944 Q6DDF0 →
STK39 STE20/SPS1-related proline-alanine-rich protein kinase 0.944 landscape →
Q8CBE3 0.942 Q8CBE3 →
Q863I2 0.942 Q863I2 →
O95199 0.942 O95199 →
Q5R650 0.941 Q5R650 →
A0A8I5ZNK2 0.939 A0A8I5ZNK2 →
Q8TBB5 0.939 Q8TBB5 →
Q9Y2I8 0.939 Q9Y2I8 →
D2XV59 0.938 D2XV59 →
Q5RCZ7 0.938 Q5RCZ7 →
Q6P798 0.938 Q6P798 →
Q99LJ7 0.938 Q99LJ7 →
Q9CZW5 0.938 Q9CZW5 →
Q6TGU2 0.938 Q6TGU2 →
Q5R8W1 0.937 Q5R8W1 →
Q75Q39 0.937 Q75Q39 →
Q58DC5 0.935 Q58DC5 →
HIRA Protein HIRA 0.934 landscape →
Q8NDN9 0.934 Q8NDN9 →
Q5R495 0.934 Q5R495 →